What is Prolacta Bioscience?
Founded in 1999 and headquartered in Duarte, California, Prolacta Bioscience® Inc. is a privately held life sciences company dedicated to Advancing the Science of Human Milk®. Prolacta is recognized as the world's leading hospital provider of 100% human milk-based nutritional products. The company's commitment to leveraging the unique benefits of human milk for infant nutrition positions it as a key player in the healthcare and biotechnology sectors. Its focus on developing specialized nutritional products for hospital use highlights a niche but critical market segment.
How much funding has Prolacta Bioscience raised?
Prolacta Bioscience has raised a total of $73.6M across 6 funding rounds:
Series A
$811K
Series B
$5M
Series C
$12M
Private Equity
$5.8M
Series D
$15M
Private Equity
$35M
Series A (2004): $811K, investors not publicly disclosed
Series B (2006): $5M led by Arcturus Capital, Gideon Hixon Fund, Mercury Fund, and Funk Ventures Capital
Series C (2007): $12M supported by DFJ Frontier, Alta Partners, Funk Ventures, DFJ Mercury, and Gideon Hixon Fund
Private Equity (2011): $5.8M, investors not publicly disclosed
Series D (2011): $15M backed by Health Evolution Partners
Private Equity (2016): $35M, investors not publicly disclosed
Key Investors in Prolacta Bioscience
Arcturus Capital
Arcturus Capital is a venture capital firm that invests in new technologies developed in sponsored research laboratories, offering unique access to advanced technology.
Gideon Hixon Fund
The Gideon Hixon Fund focuses on innovations and companies within the real estate market, leveraging extensive experience in venture capital and real estate development.
Funk Ventures Capital
Funk Ventures is a multi-faceted private equity firm with segments in venture capital, investment banking, real estate, and business services, focusing on technology, gaming, and wellness markets.
What's next for Prolacta Bioscience?
With a history of consistent capital raises, including significant private equity and venture capital rounds, Prolacta Bioscience appears to be in a scaling phase, leveraging its established position as a leading hospital provider. The recent major strategic investment suggests a focus on expanding its product offerings, enhancing its supply chain, or potentially entering new markets. Future growth will likely involve continued innovation in human milk-based nutrition and strengthening its partnerships within the healthcare ecosystem to further its mission of improving infant health outcomes.
See full Prolacta Bioscience company page
